Abstract
This review summarizes our current understanding of intracellular events in the initiation of kidney stone formation, focusing on results from studies using renal epithelial cells in vitro. Such studies have shown that oxalate – either in crystalline or in soluble form – triggers a spectrum of responses in renal cells that favor stone formation, including alterations in membrane surface properties that promote crystal attachment and alterations in cell viability that provide debris for crystal nucleation. Activation of cytosolic PLA2 appears to play an important role in oxalate actions, triggering a signaling cascade that generates several lipid mediators (arachidonic acid, AA; lysophosphatidylcholine, Lyso-PC; ceramide) that act on key intracellular targets (mitochondria, nucleus). The net effect is increased production of reactive oxygen molecules (that in turn affect other cellular processes), an increase in cell death and an induction of a number of genes in surviving cells, some of which may promote proliferation for replacement of damaged cells, or may promote secretion of urinary macromolecules that serve to modulate crystal formation. A scheme is provided that explains how such oxalate-induced alterations could initiate stone formation in vivo.
Journal Section:
Paper
References
1.
Tiselius HG: Epidemiology and medical management of stone disease. BJU Int 2003;91:758–767.
[PubMed]
2.
Cao L-C, Jonassen J, Honeyman TW, Scheid C: Oxalate-induced redistribution of phosphatidylserine in renal epithelial cells: Implications for kidney stone disease. Am J Nephrol 2001;21:69–71.
[PubMed]
3.
Verkleij AJ, Post JA: Membrane phospholipid asymmetry and signal transduction. J Membr Biol 2000;178:1–10.
[PubMed]
4.
Dennis EA: The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem Sci 1997;22:1–2.
[PubMed]
5.
Shankland SJ: New insights into the pathogenesis of membranous nephropathy. Kidney Int 2000;57:1204–1205.
[PubMed]
6.
Baggio B, Budakovic A, Nassuato MA, Vezzoli G, Manzato E, Luisetto G, Zaninotto M.: Plasma phospholipid arachidonic acid content and calcium metabolism in idiopathic calcium nephrolithiasis. Kidney Int 2000;58:1278–1284.
[PubMed]
7.
Scheid C, Honeyman T, Kohjimoto Y, Cao L-C, Jonassen J: Oxalate-induced changes in renal epithelial cell function: role in stone disease. Mol Urol 2000;4:371–382.
[PubMed]
8.
Jonassen JA, Cao LC, Honeyman TW, Scheid CR: Mechanisms mediating oxalate-induced alterations in renal cell functions. Crit Rev Euk Gene Exp 2003;13:55–72.
[PubMed]
9.
Miller C, Kennington L, Cooney R, Honeyman T, Kohjimoto Y, Cao L-C, Pullman J, Jonassen J, Scheid CR: Oxalate toxicity in renal epithelial cells: Characteristics of apoptosis and necrosis. Toxicol Appl Pharmacol 2000;162:132–141.
[PubMed]
10.
Cao L-C, Honeyman T, Jonassen J, Scheid C: Oxalate-induced ceramide accumulation in Madin-Darby canine kidney and LLC-PK1 cells. Kidney Int 2000;57:2403–2411.
[PubMed]
11.
Kolesnick RN, Kronke M: Regulation of ceramide production and apoptosis. Ann Rev Physiol 1998;60:643–665.
[PubMed]
12.
Selvam R: Calcium oxalate stone disease: Role of lipid peroxidation and antioxidants. Urol Res 2002;30:35–47.
[PubMed]
13.
Jonassen JA, Cooney R, Kennington L, Gravel K, Honeyman T, Scheid CR: Oxalate-induced changes in the viability and growth of human renal epithelial cells. J Am Soc Nephrol 1999;10:S446–S451.
[PubMed]
14.
Khan SR, Thamilselvan S: Nephrolithiasis: A consequence of renal epithelial cell exposure to oxalate and calcium oxalate crystals. Mol Urol 2000;4:305–312.
[PubMed]
15.
Thamilselvan S, Byer KJ, Hackett RL, Khan SR: Free radical scavengers, catalase and superoxide dismutase provide protection from oxalate-associated injury to LLC-PK1 and MDCK cells. J Urol 2000;164:224–229.
[PubMed]
16.
Khand FD, Gordge MP, Robertson WG, Noronha-Dutra AA, Hothersall JS: Mitochondrial superoxide production during oxalate-mediated oxidative stress in renal epithelial cells. Free Rad Biol Med 2002;32:1339–1350.
[PubMed]
17.
Fleury C, Mignotte B, Vayssiere JL: Mitochondrial reactive oxygen species in cell death signaling. Biochimie 2002;84:131–141.
[PubMed]
18.
Cao L-C, T. W. Honeyman, Scheid CR: Role of mitochondria in oxalate actions on renal cells; in Kok DJ , Romijn HC, Verhagen CMS, Verkoelen CF (eds); Eurolithiasis. 9th European Symposium of Urolithiasis. Maastricht, Shaker Publishing, 2001, pp 110–111.
19.
Strzelecki T, McGraw BR, Scheid CR, Menon M: Effect of oxalate on function of kidney mitochondria. J Urol 1989;141:423–427.
[PubMed]
20.
Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J: Osteopontin – a molecule for all seasons. Q J Med 2002;95:3–13.
21.
Asselman M, Verkoelen CF: Crystal-cell interaction in the pathogenesis of kidney stone disease. Curr Opin Urol 2002;12:271–276.
[PubMed]
22.
Lieske JC, Toback FG: Regulation of renal epithelial cell endocytosis of calcium oxalate monohydrate crystals. Am J Physiol 1993;264:F800–F807.
23.
Khan SR: Calcium oxalate crystal interaction with renal tubular epithelium, mechanism of crystal adhesion and its impact on stone development. Urol Res 1995;23:71–79.
[PubMed]
24.
Khan SR, Hackett RL: Role of organic matrix in urinary stone formation: An ultrastructural study of crystal matrix interface of calcium oxalate monohydrate stones. J Urol 1993;150:239–245.
[PubMed]
25.
Khan SR, Maslamani SA, Atmani F, Glenton PA, Opalko FJ, Thamilselvan S, Hammett-Stabler C: Membranes and their constituents as promoters of calcium oxalate crystal formation in human urine. Calcif Tissue Int 2000;66:90–96.
[PubMed]
© 2004 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2004
You do not currently have access to this content.
